TVG CEO discusses completion of recent projects
19 December 2022
TVG CEO, Jeremy Salt, discusses the recent successful completion of the Streptococcus suis and transmissible Lassa fever vaccine projects.
Menu
Our mission is to develop herpesvirus-based animal vaccines to protect against infectious diseases.
Vaccine Solutions for the 21st Century
The Vaccine Group (TVG) is using recombinant viral vector technology to develop new vaccines for use in animals to tackle diseases falling into two broad categories:
We are creating vaccine delivery platforms for viral and bacterial pathogens to address a growing number of disease issues in animals:
• Bovine tuberculosis
• Bovine mastitis
• Streptococcus suis
• African swine fever virus
• Porcine reproductive and respiratory syndrome
Latest News
TVG CEO, Jeremy Salt, discusses the recent successful completion of the Streptococcus suis and transmissible Lassa fever vaccine projects.
Most emerging infectious diseases affecting humans in the last century originated in animal reservoirs and are defined as zoonotic. Lassa fever is a significant
TVG has completed a successful Anglo-Chinese project backed by the Department of Health and Social Care (DHSC), Innovate UK, and the Chinese Ministry of
Partners
